Agree Realty Eyes CDMO Biomanufacturing Demand for Specialized Industrial and Lab Real Estate

Agree Realty Reads Biomanufacturing Signal for Real Estate Strategy

Agree Realty, a U.S. real estate investment trust known for single-tenant net-lease retail properties, is watching recent contract development manufacturing organization (CDMO) breakthroughs as a potential driver of new demand for specialized industrial and lab-capable real estate, industry sources say. The rapid advancement of complex biologics programs such as dual-payload antibody–drug conjugates (ADCs) highlights growing need for fit-for-purpose manufacturing space, and Agree Realty’s portfolio strategy may find parallels with its long-term, credit-backed leasing model as biomanufacturers seek stable, single-tenant industrial arrangements.

The surge in CDMO activity is creating requirements that differ from traditional retail or light industrial space: stringent environmental controls, specialized HVAC, redundancy in utilities, and high ceilings and clear spans for process equipment and containment. For a REIT like Agree Realty, these are both an opportunity and a strategic challenge. Opportunities include build-to-suit net leases to creditworthy biotech firms and conversions of underused retail-anchored industrial parcels; challenges include higher upfront capital and the technical complexity of meeting regulatory standards for biological manufacturing and clinical material handling.

Agree Realty is likely to evaluate partnerships, joint ventures or targeted development pipelines to capture this demand without straying from its core net-lease expertise. The company’s experience negotiating long-term tenant commitments and managing single-tenant assets can translate to stable cash flows from CDMO tenants, provided the REIT secures appropriate technical partners for facility design, permitting and operational transition. Risk management and lease structuring will be critical as biotech tenants often require bespoke buildouts, contingency for regulatory timelines and protections for sensitive clinical material.

BioDlink’s role in accelerating an ADC program

BioDlink is being credited for helping Chengdu Kanghong Pharmaceutical advance KH815, described as the first dual-payload ADC to enter clinical development, by delivering process development, analytical methods and formulation work that shorten regulatory timelines. The CDMO reports completing development and manufacturing activities 1.5 months ahead of schedule, supporting approvals in Australia and China in 2025.

Broader industry implication

BioDlink now aims to extend its CDMO footprint and partner with global biopharma firms on complex modalities. That expansion underscores a broader industry trend toward outsourcing specialized manufacturing — a trend that strengthens demand signals for purpose-built life-science real estate that REITs such as Agree Realty may track for future strategic moves.